Skip to main content

Advertisement

SpringerLink
Log in

Effectiveness of tapentadol prolonged release for the management of painful mucositis in head and neck cancers during intensity modulated radiation therapy

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

An Erratum to this article was published on 02 August 2016

Abstract

Purpose

To evaluate the effectiveness and tolerability profile of tapentadol prolonged release (PR) in a cohort of head and neck cancer (HNC) patients affected by background pain due to painful mucositis during intensity modulated radiation therapy with or without cisplatin with definitive and adjuvant intent.

Materials and methods

Tapentadol PR was administered at the moment of pain onset in opioid-naive patients at the dosage of 50 mg BID. The dosage was increased 50 mg twice a day until the optimal dose of no more than 500 mg/day of tapentadol PR. Primary endpoint of the analysis was the evaluation of improved assessment using the numerical rating scale (NRS). Secondary endpoints were as follows: (1) assessment of the treatment received using the patients’ global impression of change (PGIC) scale; (2) weight increase/stability; (3) sleep quality; and (4) tolerability. The period of observation was 90 days from the start of antineoplastic treatment.

Results

Between September 2014 and May 2015, 30 HNC patients were observed. The average age was 64.9 years (range, 36–80). Twenty-two days after the start of antineoplastic treatment, tapentadol PR was administered to 25 % of patients. This percentage was increased to 50 % after 39 days and to 75 % after 43 days. Considering the efficacy of tapentadol PR on daily pain, there was a reduction of 30 % (95 % C.I. 69.3 ÷ 96.2 %) in the pain score in 26 patients (86.7 %), and a reduction of 50 % (95 % C.I. 57.7 ÷ 90.1 %) in 23 patients (76.7 %).

Conclusion

The use of tapentadol PR is feasible and well tolerated in HNC patients affected by background pain due to painful mucositis during intensity modulated radiotherapy with or without cisplatin. Further studies are needed to enhance current findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Elting LS, Keefe DM, Sonis ST et al (2008) Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 113:2704–2713

    Article  PubMed  Google Scholar 

  2. Bossi P, Locati L, Bergamini C, Mirabile A, Granata R, Imbimbo M et al (2014) Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer. Oral Oncol 50(9):884–887

    Article  CAS  PubMed  Google Scholar 

  3. Epstein JB, Wilkie DJ, Fischer DJ, Kim YO, Villines D (2009) Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy. Head Neck Oncol 1:26

    Article  PubMed  PubMed Central  Google Scholar 

  4. Benoleil R, Epstein J, Eliav E, Jurevic R, Elad S (2007) Orofacial pain in cancer: part I: mechanisms. J Dent Res 86(6):491–505

    Article  Google Scholar 

  5. Kress HG, Koch ED, Kosturski H et al (2014) Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician 17:329–343

    PubMed  Google Scholar 

  6. Schroder W, Tzschentke TM, Terlinden R et al (2011) Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther 337:312–320

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Tzschentke TM, Christoph T, Kogel BY (2014) The muopioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs 28:319–329

    Article  CAS  PubMed  Google Scholar 

  8. Grégoire V, Langendijk JA, Nuyts S (2015) Advances in radiotherapy for head and neck cancer. J Clin Oncol 33(29):3277–3284

    Article  Google Scholar 

  9. Mazzola R, Ferrera G, Alongi F, Mannino M, Abbate B, Cucchiara T, Iacoviello G, Sciumè F, Di Paola G, Federico M, Blasi L, Lo Casto A, Lagalla R, Messana D (2015) Organ sparing and clinical outcome with step-and-shoot IMRT for head and neck cancer: a mono-institutional experience. Radiol Med 120(8):753–758

    Article  PubMed  Google Scholar 

  10. Mazzola R, Ricchetti F, Fiorentino A, Fersino S, Giaj Levra N, Naccarato S, Sicignano G, Albanese S, Di Paola G, Alterio D, Ruggieri R, Alongi F (2014) Dose-volume-related dysphagia after constrictor muscles definition in head and neck cancer intensity-modulated radiation treatment. Br J Radiol 87(1044):20140543

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Christianen ME, Langendijk JA, Westerlaan HE, van de Water TA, Bijl HP (2011) Delineation of organs at risk involved in swallowing for radiotherapy treatment planning. Radiother Oncol 101(3):394–402

    Article  PubMed  Google Scholar 

  12. Trotti A, Bellm LA, Epstein JB et al (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66:253–262

    Article  PubMed  Google Scholar 

  13. Mazzola R, Ricchetti F, Fersino S, Fiorentino A, Giaj Levra N, Di Paola G, Ruggieri R, Alongi F (2016) Predictors of mucositis in oropharyngeal and oral cavity cancer in patients treated with volumetric modulated radiation treatment: a dose-volume analysis. Head Neck 38(Suppl 1):E815–E819

    Article  PubMed  Google Scholar 

  14. Benyamin R, Trescot AM, Datta S et al (2008) Opioid complications and side effects. Pain Physician 11:S105–S120

    PubMed  Google Scholar 

  15. Bossi P, Numico G, De Santis V, Ruo Redda MG, Reali A, Belgioia L et al (2014) Prevention and treatment of oral mucositis in patients with head and neck cancer treated with (chemo) radiation: report of an Italian survey. Support Care Cancer 22(7):1889–1896

    PubMed  Google Scholar 

  16. Tzschentke TM, Jahnel U, Kogel B et al (2009) Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today (Barc) 45:483–496

    CAS  Google Scholar 

  17. Baron R, Martin-Mola E, Müller M, Dubois C, Falke D, Steigerwald I (2015) Effectiveness and safety of tapentadol prolonged release (PR) versus a combination of tapentadol PR and pregabalin for the management of severe, chronic low back pain with a neuropathic component: a randomized, double-blind, phase 3b study. Pain Pract 15(5):455–470

    Article  PubMed  Google Scholar 

  18. González Ferreira JA, Jaén Olasolo J, Azinovic I, Jeremic B (2015) Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: review of the literature. Rep Pract Oncol Radiother 20(5):328–339

    Article  PubMed  Google Scholar 

  19. Riemsma R, Forbes C, Harker J, Worthy G, Misso K, Schäfer M, Kleijnen J, Stürzebecher S (2011) Systematic review of tapentadol in chronic severe pain. Curr Med Res Opin 27(10):1907–1930, Erratum in: Curr Med Res Opin 2012; 28(1):148

    Article  CAS  PubMed  Google Scholar 

  20. Buglione M, Cavagnini R, Di Rosario F, Maddalo M, Vassalli L, Grisanti S et al (2016) Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: xerostomia and trismus (part 2). Literature review and consensus statement. Crit Rev Oncol Hematol 102:47–54

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiation Oncology, Sacro Cuore Don Calabria Cancer Care Center, Negrar-Verona, Italy

    Mazzola Rosario, Ricchetti Francesco, Fersino Sergio, Giaj Levra Niccolò, Fiorentino Alba & Alongi Filippo

  2. Medical Oncology, Sacro Cuore Don Calabria Cancer Care Center, Negrar-Verona, Italy

    Nicodemo Maurizio & Gori Stefania

  3. Head Neck Surgery, Sacro Cuore Don Calabria Cancer Care Center, Negrar-Verona, Italy

    Albanese Sergio

Authors
  1. Mazzola Rosario
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ricchetti Francesco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fersino Sergio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giaj Levra Niccolò
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fiorentino Alba
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nicodemo Maurizio
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Albanese Sergio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gori Stefania
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Alongi Filippo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mazzola Rosario.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rosario, M., Francesco, R., Sergio, F. et al. Effectiveness of tapentadol prolonged release for the management of painful mucositis in head and neck cancers during intensity modulated radiation therapy. Support Care Cancer 24, 4451–4455 (2016). https://doi.org/10.1007/s00520-016-3351-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-016-3351-7

Keywords

Search

Navigation